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 Background - Flebogrif® (Balton, Poland) is a novel 
mechanochemical ablation (MOCA) device for 
saphenous vein insufficiency. It combines endothelial 
damage performed by radial retractable cutting hooks 
together with chemical ablation through sclerosant 
injection of 3% polidocanol foam according to its 
IFU. The objective of this study is to evaluate 
Flebogrif’s efficacy in terms of recanalization rate and 
recurrence by varying polidocanol foam 
concentrations. 
 
Methods - We performed 24 MOCAs on 23 patients 
with Flebogrif® between January and May 2019. In 
12 cases the polidocanol foam was prepared at a 3% 
concentration, and in another 12 at 1.5%. Great 
saphenous vein (GSV) recanalization and truncular 
recurrence were evaluated at 1 and 3 months with a 
Duplex Ultrasound Anatomy (DUS) examination. 
 
Results – At 1- and 3-month follow-ups, none of the 
14 patients treated with the polidocanol 3% foam were 
observed to have had great saphenous vein GSV 
recanalization and truncular recurrence. Only 2 of the 
14 (14.3%) cases treated with polidocanol 1.5% foam 
showed evidence of recanalization within the first 
centimetres from the sapheno-femoral junction (p > 
.05). All patients experienced clinical benefits without 
recurrence of symptoms. 
 
Conclusion - MOCA with Flebogrif® is a safe, 
relatively inexpensive and effective alternative to 
standard methods in the treatment of saphenous 
insufficiency with encouraging short-term results. 
Despite our relatively small patient sample, no 
statistical significance in evidence of recurrence in the 
group of patients treated with 3% foam and those 
treated with 1.5% foam was noted. Longer term 
analysis of GSV patency and recurrence is necessary 
to further evaluate Flebogrif’s impact and actual 




Endovascular techniques for the treatment of 
saphenous vein insufficiency have been increasing in 
number and complexity over the last years. Among 
them, endovenous laser ablation (EVLA) and 
radiofrequency ablation (RFA) are now considered 
first-choice treatments, according to the latest 
guidelines for truncal ablation.1  
In the already crowded phlebological panorama, 
mechanochemical ablation (MOCA) is a recently 
introduced mechanism which combines chemical 
damage through sclerosant foam injection with an 
endothelial spasm performed by a rotating wire or 
radial cutting hooks commercially patented as 
Clarivein® (Merit Medical, Utah, USA) and 
Flebogrif® (Balton, Poland), respectively. The 
endothelial and medial mechanical damage is 
purported to enhance the penetration of the sclerosant 
in the vessel wall and the subsequent vasoconstriction 
as proven in ex vivo and animal models.2,3 Thus it is 
reasonable to assume that recanalization rates would 
be lower than with mechanical or chemical ablation 
treatments alone.  
 
Clarivein 
Being the first MOCA device ever produced and 
studied, Clarivein® has experienced broad success 
and wide application, including in the treatment of 
venous leg ulcers.4,5 It has been also compared to 
other techniques such as EVLA and RFA with 
satisfying results, proving a high safety profile and 
low recanalization rates.6,7  Results from a 
randomized controlled trial published in December 
2019 confirm  shorter operative time, lower rates of 
postoperative phlebitis and significantly shorter time 
to return to work   following treatment8. 
 
Flebogrif 
As of yet, evidence is still scarce on Flebogrif. 
Zubilewicz et al.9 reported a 93% occlusion rate at 
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three months and only 1 deep vein thrombosis 
complication in a cohort of 200 patients. Unlike 
Clarivein®, no study has yet been conducted which 
observes the histological effects of Flebogrif cutting 
hooks on the endothelium and whether it indeeds 
increases sclerosant penetration in the vessel wall, nor 
has a comparison been made on its benefit over other 
comparable techniques.  
According to the Instructions for Use, both Clarivein 
and Flebogrif® require a preparation of 2-3% 
polidocanol foam to be injected while the system is 
retracted though the trunk to be ablated. On the other 
hand, the use of 1 or 1.5% foam concentration even in 
large vessels such as the great saphenous vein at the 
sapheno-femoral junction (SFJ) is considered safe as 
reported in the literature.10  
The objective of this study is to evaluate Flebogrif’s 
efficacy in terms of the recanalization rate and 





Among patients with primary varicose disease we 
included those reporting chronic venous disease 
symptoms (leg heaviness and swelling, pruritus, etc.), 
evidence of reflux at the SFJ; a linear GSV - without 
big, tortuous truncular collaterals - and a diameter of 
the GSV at level of the SFJ diameter no bigger than 
60 mm.  
Based upon these criteria, we selected 23 suitable 
patients and performed 24 MOCAs with Flebogrif® 
between January and May 2019. In 12 cases 
polidocanol foam was prepared at a 3% concentration, 
and in another 12 at a 1.5% concentration (figure 1).  
 
Polidocanol % 1,5 3 Tot. 
N. patients 11 12 23 
Sex 
 
N.  % 
M 2 2 4 17.4% 
F 9 10 19 82.6% 
Figure 1. Distribution of patients between the two groups: 
1.5% and 3% polidocanol foam concentrations.  
 
No statistical significance regarding the diameter of 
GSV at 2 centimeters from SVJ (Figure 2) existed. 
Thus, GSV recanalization and truncular recurrence 
were analysed at 1 and 3 months with a DUS 
examination. Statistical analysis was performed with 
IBM SPSS.  
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% 
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Figure 2. Comparison between the two groups according 





At 1-and 3-month follow-ups, no GSV recanalization 
and truncular recurrence in any of the 14 patients 
treated with polidocanol 3% foam was observed. Only 
in 2 of the 14 (14.3%) cases treated with polidocanol 
1.5% foam was there evidence of recanalization in the 









1.5 % 12 2 10 83.3% 
3.0 % 12 0 12 100% 
Global 24 2 22 91.7% 
Figure 3. Occlusion rates at 3 months. 
 
Follow-up data were also processed through Kaplan-
Meyer analysis showing no statistical significance 
between the two groups in the first 3 months of 
follow-up (figure 4). All patients experienced good 
aesthetical results with no recurrence of symptoms.  
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IV. DISCUSSION 
 
Over the last few decades, the undiscussed role of 
classical surgical saphenous ablation in the different 
forms of stripping has been widely called into 
question, although the short groin incision – with 
limited risk of lymphocele and excellent cosmetic 
results – and mandatory isolation of the saphenous 
nerve at the medial malleolus, have sensitively limited 
its major complication rates.11  
The progressive trend of abandonment of such 
surgical procedures started in the United States since 
the introduction of endovascular thermal techniques, 
initially without solid proof of benefits and a non-
negligible rate of complication including thermal 
injury of the skin, deep vein thrombosis and 
recanalization.6 
Already in the 2011 Clinical practice guidelines of the 
Society for Vascular Surgery and the American 
Venous Forum, surgery is restricted to patients with 
large, tortuous and superficial saphenous veins or to 
those having aneurysmal enlargement at SFJ.12 As 
well, the 2017 American College of Phlebology 
Guidelines also recommend endovenous thermal 
ablation as the preferred treatment for saphenous and 
accessory saphenous vein incompetence, and advise 
the use of mechanical/chemical ablation with 
Clarivein to treat truncal venous reflux, but with a 
lower level of evidence.13 In parallel, ultrasound-
guided foam sclerotherapy (UGFS) has reached a 
prominent position among the saphenous ablation 
techniques being considered as safe and effective a 
procedure as thermal techniques.12,13 
According to the latest Guidelines from the European 
Society for Vascular Surgery (June 2015), RFA and 
EVLA are preferred over both surgery and foam 
sclerotherapy with an evidence of Grade I, Level A.14 
Despite all these recommendations, there is still a lack 
of evidence of exhaustive long-term results 
comparing open surgery, foam sclerotherapy and 
endovascular procedures, giving univocal solutions or 
shared work-up algorithms for the treatment of 
saphenous insufficiency. According to the LARA and 
RECOVERY studies and recent reviews,15-17 RFA is 
equivalent to EVLA in terms of occlusion rates, 
however it causes less post-operative pain and 
bruising with a faster return to normal activities,  
In several studies18-20 UGFS appear less effective than 
EVLA and/or RFA. A recent RCT of an eight-year 
follow-up claims that surgical stripping has a 
technically better outcome in terms of recurrence of 
GSV and SFJ reflux than UGFS in the long term, and 
that long-term follow-up suggests significant clinical 
progression of venous disease as measured by VCSS 
in both groups, but less so after surgery.21  
Most of the studies available regarding the follow-up 
of mechanochemical ablation (all of which are on 
Clarivein®) are in the short-term and report good 
results, short operative time, high patient acceptance, 
low peri-procedural pain and no saphenous nerve 
injury.4,22,23 This is also confirmed when MOCA is 
compared to EVLA and RFA.6,7 
Despite the absence of evidence on Flebogrif® in the 
short and mid-terms and no comparisons to any other 
truncal ablation techniques yet existing, in our 
experience Flebogrif® appears to have the same 
advantages as those observed for its counterpart 
Clarivein®, allowing for short, painless procedures 
with no need of tumescent anaesthesia. The operation 
can also be performed in an out-patient setting, has a 
fast recovery period and overall lower costs, 
especially if compared to EVLA or RFA.    
The limitations of this study are the small number of 
cases and the short follow-up period.  Also, the 
Flebogrif® procedures were performed in patients 
with relatively small incompetent GSV, and no 
comparison with other techniques has been made.  
Further investigation is required to broaden the 
number of treated cases, extend the follow-up period 
and should include a comparison with surgical or 





MOCA with Flebogrif® is a safe, relatively 
inexpensive and effective alternative to standard 
methods (i.e. surgical treatment, thermal ablation, 
etc.) in the treatment of saphenous insufficiency, with 
encouraging results reported in the short term. Despite 
our relatively small patient sample, no statistical 
significance was found in evidence of recurrence in 
the group of patients treated with 3% foam and in 
those treated with 1.5% foam. Long term analysis of 
GSV patency and recurrence is necessary to evaluate 
its impact and actual indications in the treatment of 
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